<- Go Home
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Market Cap
$801.0M
Volume
275.6K
Cash and Equivalents
$25.4M
EBITDA
-$67.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$17.5M
Profit Margin
100.00%
52 Week High
$50.40
52 Week Low
$16.54
Dividend
N/A
Price / Book Value
3.77
Price / Earnings
-12.14
Price / Tangible Book Value
3.77
Enterprise Value
$599.8M
Enterprise Value / EBITDA
-8.94
Operating Income
-$67.9M
Return on Equity
28.78%
Return on Assets
-19.52
Cash and Short Term Investments
$202.2M
Debt
$954.0K
Equity
$193.9M
Revenue
$17.5M
Unlevered FCF
-$25.2M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium